Anda belum login :: 17 Aug 2022 18:00 WIB
Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study
Tershakovec, Andrew M.
Keane, William F.
Lyle, Paulette A.
Appel, Gerald B.
Article from Journal - ilmiah internasional
Diabetes Care vol. 31 no. 03 (Mar. 2008)
chronic kidney disease
end-stage renal disease
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
1 (dapat dipinjam: 0)
Lihat Detail Induk
Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.
Klik untuk menuliskan opini Anda tentang koleksi ini!
Copyright © 2006, 2007
Unika Atma Jaya
, all rights reserved
Process time: 0.015625 second(s)